Skip to main content

Progesterone Receptor Negative clinical trials at UC Davis
4 research studies open to eligible people

  • A Study of Mammographic Breast Density For Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

    open to eligible females

    This phase III trial evaluates mammographic breast density in participants with hormone receptor-negative breast cancer enrolled on study A011502. High breast density has been shown to be a strong risk factor for developing breast cancer and decreasing breast density may decrease the risk for breast cancer. Participants treated with aspirin may show reduced breast density on a mammogram.

    Sacramento, California and other locations

  • A Study of the Experimental Combination of Cediranib and Olaparib in Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

    Sacramento, California and other locations

  • Patients With Triple Negative Breast Cancer: Chemotherapy Before Surgery With an Experimental Immune System Therapy Cancer Drug

    β€œThe purpose of this study is to compare any good and bad effects of the study drug Atezolizumab.”

    open to eligible females ages 18 years and up

    This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

    Sacramento, California and other locations

  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

    open to eligible people ages 18 years and up

    This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Sacramento, California and other locations

Last updated: